From Financial Modeling Prep: 2025-03-11 07:00:06

Verona Pharma plc (NASDAQ:VRNA) is a pharmaceutical company specializing in respiratory disease treatments like COPD and asthma. Competitors include Immuron Limited, Rhythm Pharmaceuticals, Milestone Pharmaceuticals, Akero Therapeutics, and Mersana Therapeutics.

Verona Pharma’s ROIC is -37.67% compared to a WACC of 5.93%, resulting in a ratio of -6.35. Immuron Limited’s ROIC is -46.07% with a WACC of 10.83%, leading to a ratio of -4.26, indicating better efficiency.

Rhythm Pharmaceuticals and Milestone Pharmaceuticals have negative ROIC values of -96.06% and -55.81% with WACC figures of 15.48% and 9.62%, resulting in challenging ROIC to WACC ratios.

Akero Therapeutics and Mersana Therapeutics struggle with ROIC to WACC ratios of -7.32 and -4.27, respectively. Akero’s ROIC of -36.27% against a WACC of 4.95% reflects difficulty in generating returns, similar to Mersana’s challenges.



Read more at Financial Modeling Prep:: Verona Pharma plc (NASDAQ:VRNA) Financial Efficien…